Israel Englander Atea Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $609,233 - $899,063	197,163 Added 1263.87%	212,763 $859,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $146,132 - $174,836	-52,190 Reduced 76.99%	15,600 $47,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $15,626 - $24,632	-4,868 Reduced 6.7%	67,790 $253,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $321,084 - $531,929	-107,028 Reduced 59.56%	72,658 $243,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $781,634 - $1.11 Million	179,686 New	179,686 $864,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $275M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.